Japan’s ReproCell Biotech To Be First To Commercialize iPS Cells
This article was originally published in PharmAsia News
Executive Summary
ReproCell, a Japanese biotech start-up, is expected be the nation's first company to produce and market a human induced pluripotent stem cell product. The plan is to use iPS cells created at Kyoto University as the basis for a service to detect the side effects of drugs. The company already had been producing the cells using monkey embryonic stem cells. The market for such diagnoses are pharmaceutical firms that seekd to avoid costly side effects that interfere with clinical trials. (Click here for more - a subscription may be required